Eye implant aims to reduce injections for blinding eye disease
Disease control
Completed
This study tested a new, long-acting eye implant called EYP-1901 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to see if the implant, which slowly releases medicine, could work as well as or better than the standard treat…
Phase: PHASE2 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC